Meeting
2017 ASCO Annual Meeting
Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma (HL): A Children’s Oncology Group (COG) report.
Authors
Peter D. Cole
The Children's Hospital at Montefiore, Bronx, NY
Peter D. Cole , Kathleen McCarten , Monika Metzger , Richard A. Drachtman , Terzah M. Horton , Qinglin Pei , Rizvan Bush , Susan Blaney , Brenda Weigel , Kara M. Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT01780662
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7527)
DOI
10.1200/JCO.2017.35.15_suppl.7527
Abstract #
7527
Poster Bd #
289
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.
First Author: Peter D. Cole
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2022 ASCO Annual Meeting
Checkpoint inhibitor and multireceptor tyrosine kinase inhibitor combination in relapsed refractory sarcomas: A single institution series.
First Author: Nupur Mittal
Poster
2022 ASCO Annual Meeting
A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
First Author: Viswatej Avutu